Synergy Pharma

At #ACG2018, Synergy Pharmaceuticals will present outcomes from a post-hoc analysis of two trials which studied the safety and efficacy of a treatment for CIC in patients receiving concomitant acid suppression therapy. Find out more here: ow.ly/S7bM30m8Omh $SGYP #ACG2018

At #ACG2018, Synergy Pharmaceuticals will present outcomes from post-hoc analyses of trials which studied adult patients ≥65, a group in which constipation is prevalent and there are limited data. Find out more on these analyses here: ow.ly/AFgV30m8Olm $SGYP #ACG2018

Synergy Pharmaceuticals to present new analyses that further reinforce effectiveness and safety in important subpopulations of adults with CIC or IBS-C at the @AmCollegeGastro Annual Scientific Meeting next week. More info: ow.ly/tODo30m2R7h $SGYP #ACG2018

Synergy Pharmaceuticals announces new formulary wins improving 2018 and 2019 coverage status across major U.S. Commercial, Medicare Part D and Managed Medicaid plans. Read the full press release: ow.ly/GV1V30lWFey $SGYP

Synergy Pharmaceuticals reports Q2 2018 financial and business results. Read the update: ow.ly/Ayqe30ljeQk $SGYP

Synergy Pharmaceuticals announces major coverage win with @ExpressScripts. Get the details: ow.ly/5YvV30liIaz $SGYP

Synergy Pharmaceuticals secures licensing deal in China with Luoxin Pharmaceutical Group Co., Ltd. Read more: ow.ly/4DLI30liyOM $SGYP

Synergy Pharmaceuticals presents new data at Digestive Disease Week. Find the details here ow.ly/1rhg30klAka @DDWmeeting #DDW2018 $SGYP

Synergy Pharmaceuticals highlights new data at Digestive Disease Week linking uroguanylin deficiency to CIC and IBS-C. Find the details here ow.ly/MFFA30klz5y @DDWmeeting #DDW2018 $SGYP

Synergy Pharmaceuticals to present new data at Digestive Disease Week. Find the details here ow.ly/OWpx30kegvo @DDWmeeting #DDW2018 $SGYP

HAPPENING NOW: Tune in to our live conference call and webcast to hear Synergy management discuss our 1Q 2018 financial and business results: ow.ly/B0uC30jWbTu $SGYP

Synergy reports 1Q 2018 financial and business results. Get the details: ow.ly/NrA630jWcZ6 $SGYP

Synergy to host conference call and webcast to discuss financial and operating results for Q1 2018 on Thursday, 5/10 at 4:30 p.m. EDT. Get the details: ow.ly/KzQK30jGckn

#IBS is the 7th most common diagnosis by primary care physicians in the US, affecting millions of people. Learn more: ow.ly/zuWr30jmeTo #IBSAwarenessMonth

On average, #IBS leads to 2 missed days of school/work and 9 days of impacted productivity each month. #IBSAwarenessMonth

Nearly 1 in 4 of people living with #IBS report that they cannot accurately predict if they will experience symptoms on any given day. #IBSAwarenessMonth

April is Irritable Bowel Syndrome (#IBS) Awareness Month. #DYK that 1 in 20 people in the U.S. lives with IBS-C? #IBSAwarenessMonth

TODAY: Synergy CEO Troy Hamilton to present at the Oppenheimer Healthcare Conference: ow.ly/wIkw30j3Vi3 $SGYP

Synergy's Troy Hamilton to present at the Oppenheimer Conference on 3/20. Learn more: ow.ly/9uDl30iUUuI $SGYP

How many Americans are living with #IBS-C? ow.ly/aBE130iFWOA